Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin

Lancet Oncology

Volumn 5, Issue 9, 2004, Pages 575-577

  Jones, Robin L ^a   Berry, Gerald J ^b   Rubens, Robert D ^c   Miles, David W ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; LIPOSOME; METHOTREXATE; PAMIDRONIC ACID; RADIOISOTOPE; TAMOXIFEN; VINCRISTINE;

ABDOMINAL PAIN; ADULT; ARM DISEASE; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CARDIOTOXICITY; CASE REPORT; CERVICAL LYMPH NODE; CLINICAL TRIAL; DISEASE COURSE; DRUG FORMULATION; DRUG RESPONSE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; LETHARGY; LIMB PAIN; LYMPHADENOPATHY; MYOCARDIAL DISEASE; OVARY DISEASE; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; SPLEEN CANCER; TUMOR BIOPSY;

ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CLINICAL TRIALS; DOXORUBICIN; FEMALE; HEART; HUMANS; LYMPHATIC METASTASIS; MICROSCOPY, ELECTRON; MIDDLE AGED; MYOCARDIUM; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

EID: 4444300900     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01570-0     Document Type: Article

References (10)

1. Singal PK Iliskovic N. Doxorubicin-induced cardiomyopathy N Engl J Med 339 1998 900-905
2. Safra T Muggia F Jeffers S et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2 Ann Oncol 11 2000 1029-1033
3. Safra T. Cardiac safety of liposomal anthracyclines Oncologist 8 suppl 2 2003 17-24
4. Working PK Newman MS Sullivan T Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes J Pharmacol Exp Ther 289 1999 1128-1133
5. Harris L Batist G Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial a first-line therapy of metastatic breast carcinoma Cancer 94 2002 25-36
6. Wigler N. O'Brien M. Rosso R. et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) vs doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21: abstr 177.
7. Mlineritsch B Mayer P Moik M et al. Phase II study of pegylated liposomal doxorubicin (Caelyx)-monotherapy in previous treated metastatic breast cancer Breast Cancer Res Treat 69 2001 287
8. Slamon DJ Leyland-Jones B Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783-792
9. Theodoulou M. Campos S.M. Batist G. et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 2002; 21: 55 (abstr).
10. Trigo J. Climent M.A. Lluch A. et al. Liposomal doxorubicin Myocet in combination with Herceptin and paclitaxel is active and well tolerated in patients with HER-2 positive locally advanced breast cancer: a phase II study. Breast Cancer Res Treat 2003; 82 (suppl): S83.